The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II trial of olaparib in combination with eribulin in patients with advanced or metastatic triple negative breast cancer (TNBC) previously treated with anthracyclines and taxanes: First results from phase I.
 
Hiroyuki Yasojima
No Relationships to Disclose
 
Harukaze Yamamoto
No Relationships to Disclose
 
Norikazu Masuda
Honoraria - AstraZeneca; Chugai Pharma; Eisai; GlaxoSmithKline; Kyowa Hakko Kirin; Sanofi
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kenjiro Aogi
Honoraria - AstraZeneca; Becton Dickinson; Chugai Pharma; Daiichi Sankyo; Eisai; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical
 
Masato Takahashi
No Relationships to Disclose
 
Kan Yonemori
No Relationships to Disclose
 
Masahiro Takeuchi
Honoraria - Japan Clinical Cancer Research Organization
Consulting or Advisory Role - AstraZeneca; Sanofi; Taiho Pharmaceutical
 
Akinobu Hamada
No Relationships to Disclose
 
Kenji Tamura
Honoraria - AstraZeneca; Eisai; Taiho Pharmaceutical
Research Funding - Eisai (Inst)
 
Tamie Sukigara
No Relationships to Disclose
 
Ritsuko Nagasaka
No Relationships to Disclose
 
Rie Nakano
No Relationships to Disclose
 
Yukie Tsujimoto
No Relationships to Disclose
 
Yuka Morioka
No Relationships to Disclose
 
Kiyomi Higuchi
No Relationships to Disclose
 
Yasuhiro Fujiwara
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Sanofi; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Lilly (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)